Department of Pediatrics, Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California Los Angles, Los Angeles, CA, United States.
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angles, Los Angeles, CA, United States.
J Appl Lab Med. 2024 Jan 3;9(1):14-27. doi: 10.1093/jalm/jfad083.
The Karius Test (KT), a cell-free DNA metagenomic next-generation sequencing assay, has potential to improve diagnostic evaluation of infectious diseases. Published data describing clinical impact of positive KT results are limited. We attempt to elucidate the clinical interpretation and impact of positive KT results based on types and patterns of detected pathogens and patient characteristics.
All positive KT results from a single institution in 2022 were screened. Patients with results that met predefined categories were included for review by a panel of 3 infectious diseases physicians and one clinical microbiologist. Predefined categories included reports with fungal, parasitic, notable bacterial, notable viral pathogens, or polybacterial results (≥3 bacteria). Polybacterial results were further classified into patterns of microbiome detected. Clinical impact and its correlation with result or patient characteristics were explored.
Ninety-two patients met the inclusion criteria, most were immunocompromised (73%). Positive KT results that met predefined categories had the following clinical impact: positive in 30.4%, negative in 2.2%, and none in 65.2%. Polybacterial results, especially interpreted as oral flora had lowest clinical impact (7.1% and 0.0%, respectively), while detection of parasites or notable bacterial pathogens had the highest clinical impact (100% and 77.8%, respectively). There was no correlation between patient characteristics and clinical impact.
Among a cohort of largely immunocompromised patients, we were able to demonstrate clinical impact of specific KT result types and patterns but did not find correlation between patient characteristics and clinical impact. Our results should be confirmed in future larger cohorts.
Karius 测试(KT)是一种无细胞游离 DNA 宏基因组下一代测序检测,有可能改善传染病的诊断评估。描述阳性 KT 结果临床影响的已发表数据有限。我们试图根据检测到的病原体类型和模式以及患者特征来阐明阳性 KT 结果的临床解释和影响。
筛选了 2022 年一家单机构的所有阳性 KT 结果。符合预定义类别标准的患者由 3 名传染病医生和 1 名临床微生物学家组成的小组进行审查。预定义类别包括真菌、寄生虫、显著细菌、显著病毒病原体或多细菌(≥3 种细菌)结果的报告。多细菌结果进一步分为检测到的微生物组模式进行分类。探讨了临床影响及其与结果或患者特征的相关性。
92 名患者符合纳入标准,大多数为免疫功能低下(73%)。符合预定义类别的阳性 KT 结果具有以下临床影响:阳性 30.4%,阴性 2.2%,无影响 65.2%。多细菌结果,尤其是解释为口腔菌群的结果,临床影响最低(分别为 7.1%和 0.0%),而寄生虫或显著细菌病原体的检测具有最高的临床影响(分别为 100%和 77.8%)。患者特征与临床影响之间无相关性。
在一组以免疫功能低下患者为主的队列中,我们能够证明特定 KT 结果类型和模式的临床影响,但未发现患者特征与临床影响之间存在相关性。我们的结果应在未来更大的队列中得到证实。